Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies
Authors:
Open Access
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 43 (5) , 822-835.e16
Abstract
No abstract availableKeywords
Funding Information
- Daiichi Sankyo Co Ltd
This publication has 21 references indexed in Scilit:
- Neuropathic PainSeminars in Neurology, 2018
- Executive summary of the Clinical Guidelines of Pharmacotherapy for Neuropathic Pain: second edition by the Japanese Society of Pain CliniciansJournal of Anesthesia, 2018
- Neuropathic painNature Reviews Disease Primers, 2017
- The prevalence and impact of chronic neuropathic pain on daily and social life: A nationwide study in a Japanese populationEuropean journal of pain, 2017
- Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic useExpert Review of Neurotherapeutics, 2016
- Suboptimal Treatment of Diabetic Peripheral Neuropathic Pain in the United StatesPain Medicine, 2015
- Neuropathic Pain: Principles of Diagnosis and TreatmentMayo Clinic Proceedings, 2015
- Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysisThe Lancet Neurology, 2015
- Neuropathic pain in the general population: A systematic review of epidemiological studiesPain, 2014
- Therapeutic Options for the Treatment of Postherpetic Neuralgia: A Systematic ReviewJournal of Pain & Palliative Care Pharmacotherapy, 2013